Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Trientin (ATC-Code nach WHO: A16AX12)

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

September 30, 2026
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) by way of an open-house model for the active ingredient trientine (ATC code according to WHO: A16AX12)

This is one of 1,390 active Germany Pharmaceuticals opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedAugust 01, 2025
Procurement stageActive solicitation
Response dueSeptember 30, 2026
StatusOpen — accepting responses
TranslationTranslated from German by GlobalGov’s translation pipeline
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Natriumoxybat (ATC-Code nach WHO: N07XX04)
Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Tetrabenazin (ATC: N07XX06)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Axitinib (ATC-Code nach WHO: L01EK01)
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-19 - Tafamidis
Germany – Pharmaceutical products – OpenHouse-Verfahren Diverse Arzneimittelwirkstoffe ab 01.10.2025
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Liraglutid, ATC A10BJ02
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Sultamicillin (ATC J01CR04).
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Sunitinib, ATC L01EX01

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.